What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Neurotech International

Home
Australia
Nedlands, WA
Neurotech International

Neurotech is a biopharmaceutical company focused on the development and commercialisation of neurological solutions that improve quality of life.

Our current focus is the ground-breaking NTI164 treatment in children with neurological disorders. Our current development program is a world-first clinical trial using NTI164 to treat Paediatric Autism Spectrum Disorder (ASD) at Monash Children’s Hospital, Melbourne. Phase I/II trial results demonstrated successful outcomes relating to the safety, tolerability and efficacy of NTI164 on key behavioural parameters with 93% of participants showing symptom improvement.

29/08/2023

BREAKTHROUGH IN RETT SYNDROME RESEARCH! 🌟

We're proud to share that Neurotech is making history with the world's first human clinical study to address Rett syndrome in children.

Introducing NTIRTT1, an innovative single-arm, open-label, Phase I/II clinical trial. We are seeking 14 paediatric patients diagnosed with Rett syndrome to evaluate the efficacy and safety of orally administered NTI164, a medicinal cannabis derived biopharmaceutical.

The trial is currently underway at the Children's Hospital at Westmead, Sydney, Australia. Behind this groundbreaking study is Associate Professor Carolyn Ellaway, a Clinical Geneticist in Metabolic Genetics at the New South Wales Genetic Metabolic Disorders Service, a part of the esteemed Sydney Children's Hospital Network.

Subscribe to our newsletter to stay up-to-date: www.neurotechinternational.com 📰

International Rett Syndrome Foundation

27/08/2023

Neurotech is leading the way with the world's first human clinical trial to treat children diagnosed with Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), collectively known as PANS/PANDAS.

These children experience a sudden onset of neuropsychiatric symptoms, such as Obsessive-Compulsive Disorder (OCD) and restrictive eating, often within just one day.

The study is currently being conducted at two esteemed centres in Australia: the Children's Hospital at Westmead, Sydney, and the Paediatric Neurology Unit at Monash Medical Centre, Melbourne. Under the guidance of Professor Russell Dale, a world-renowned expert on PANS/PANDAS, we are determined to make a positive impact on these children's lives.

Stay in the know with all the latest updates and announcements by subscribing to our newsletter at www.neurotechinternational.com 📰

24/08/2023

We're passionate about making a positive impact on neurology and committed to finding solutions with NTI164, a medicinal cannabis-derived biopharmaceutical.

Learn more at neurotechinternational.com 💚

22/08/2023

WHY NTI164? 🌿

➡ High level of CBDA + an assortment of other minor cannabinoids

➡ This unique combination works differently to CBD- it has powerful effects on inflammatory pathways and suppress cytokine activity. It also contains less than 0.3% TH

➡ The unique combination of CBDA and other ‘minor’ cannabinoids work together to create an “entourage effect” that is more potent than CBD isolate.

➡ Multi-functional mode of action – neuro-protection, neuro-modulation and neuro-regulation.

Learn more about the potential of NTI164 at neurotechinternational.com

Autism Awareness Australia

20/08/2023

How we're changing lives of families and children with Autism 🌟

At Neurotech International, we believe in the potential of every child, and we're paving the way for progress in neurological disorders.

ASD is not an intellectual disability or a mental health condition – it is a complex neurodevelopmental condition involving persistent challenges with social communication, restricted interests, and repetitive behaviour.

At Neurotech, we have the exclusive worldwide licence for NTI164, a medicinal cannabis derived biopharmaceutical, for the treatment of paediatric neurological disorders including ASD.

📧 Subscribe to our e-newsletter for latest updates: www.neurotechinternational.com

Autism Awareness Australia

17/08/2023

Who agrees? 🙋‍♀️🙋🙋‍♂️

15/08/2023

WHAT WE DO

Neurotech International is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders.

Our current clinical programs give genuine hope to families who have children diagnosed with severe Autism (ASD), PANS/ PANDAS , Rett syndrome and cerebral palsy.

To follow clinical trial updates:
💻www.neurotechinternational.com

Autism Spectrum Australia (Aspect) International Rett Syndrome Foundation Rett Syndrome Association of Australia Inc.- RSAA

13/08/2023

It is the groundbreaking trial giving hope to families of children living with autism, leading one mother to declare she’s gotten her “child back”.

Meet Carla Gravagna, mother to 13-year-old Melbourne boy Matteo who has Autism Spectrum Disorder (ASD), ADHD and epilepsy.

Matteo Gravagna is one out of twelve children with autism who were given an experimental medicinal cannabis product as part of a trial run by Monash Children’s Hospital.

“Matteo now sleeps through the night and goes to school four or five days a week and can participate in school excursions. He can tolerate daily activities that were impossible for him before, like being in a supermarket for an hour.""

“This is a strong indication that NTI164 has the potential to be an enabling treatment for some of the symptoms that cause people with Autism Spectrum Disorder distress,” Professor Michael Fahey.

To stay up to date, subscribe to our newsletter for all announcements at www.neurotechinternational.com

10/08/2023

We're transforming the lives of families and children across Australia through innovation. To stay up to date with our trials and latest news, subscribe to our newsletter: www.neurotechinternational.com

08/08/2023

Neurotech International is dedicated to making a positive impact on the field of neurology and improving the lives of those affected by neurological disorders through our four core strategies:

☑️Focus on paediatric patients
☑️Focus On Rare Neurological Disorders with Neuroinflammation
☑️Focus on Partnering with Key Opinion Leaders / Clinicians
☑️Focus on drug product development

Subscribe to our e-newsletter to stay up-to-date with our progress.

💻 www.neurotechinternational.com

International Rett Syndrome Foundation

06/08/2023

Neurotech receives HREC Approval for Phase I/II Clinical Trial in Rett Syndrome ✅

The trial will be conducted across three centres in Australia with Principal Investigator Associate Professor Carolyn Ellaway, Senior Staff Specialist NSW Genetic Metabolic Disorders Service, the Sydney Children’s Hospital Network and Metabolic Genetics at The Children's Hospital at Westmead and Associate Principal Investigators Professor Michael Fahey, Head of the Paediatric Neurology Unit at Monash Medical Centre, Director of Neurogenetics and Dr Giuliana Antolovich, Department of Neurodevelopment & Disability, Royal Children’s Hospital Melbourne.

Patient recruitment is expected to commence in early Q3 CY2023. The preliminary (top-line) results of the trial are anticipated in Q1 CY2024.

To stay updated with results, subscribe to our e-newsletter online:
💻 www.neurotechinternational.com

International Rett Syndrome Foundation
Rett Syndrome Association of Australia Inc.- RSAA

03/08/2023

It is in our differences that we find our greatest strengths.

Together, we're determined to provide fresh hope to families and children with severe autism.

To follow our journey and stay up-to-date with our clinical trials, visit neurotechinternational.com to subscribe to our e-newsletter.

Address

Suite 5 CPC, 145 Stirling Highway
Nedlands, WA
6009

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+61893893130

Website

https://neurotechinternational.com/

Alerts

Be the first to know and let us send you an email when Neurotech International posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Neurotech International:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Want your practice to be the top-listed Clinic in Nedlands?